Pubblicazioni

Pubblicazioni

Role of climate in the spread of shiga toxin-producing Escherichia coli infection among children.
Acquaotta F, Ardissino G, Fratianni S, Perrone M.
Int J Biometeorol. 2017 Sept;  61(9):1647-1655 doi 10.1007/s00484-017-1344-y
PMID: 28389880

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.
Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, Grovetto E, Possenti I, Perrone M, Testa S, Paglialonga F, Messa P, Cugno M.
Pediatr Nephrol. 2017 Oct 18. doi: 10.1007/s00467-017-3813-2. [Epub ahead of print]
PMID: 29046944

Late Onset Cobalamin Disorder and Hemolytic Uremic Syndrome: A Rare Cause of Nephrotic Syndrome.
Ardissino G, Perrone M, Tel F, Testa S, Morrone A, Possenti I, Tagliaferri F, Dilena R, Menni F.
Case Rep Pediatr. 2017; 2017:2794060. doi: 10.1155/2017/2794060. Epub 2017 Aug 1.
PMID:28835862

Comment to "Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea-associated hemolytic uremic syndrome" by Keenswijk et al. Eur J Pediatr 2017; 176(3): 355-360.
Ardissino G, Tel F, Picicco D, Dodaro A, Daprai L, Consolo S, Testa S, Paglialonga F, Consonni D; ItalKid HUS Network.
Eur J Pediatr. 2017 Aug 19. doi: 10.1007/s00431-017-2989-6. [Epub ahead of print] No abstract available.
PMID:28823076

Role of climate in the spread of shiga toxin-producing Escherichia coli infection among children.
Acquaotta F, Ardissino G, Fratianni S, Perrone M.
Int J Biometeorol. 2017 Apr 7. doi: 10.1007/s00484-017-1344-y. [Epub ahead of print]
PMID: 28389880

Efficacy of eculizumab in a case of pregnancy-associated aHUS.

Cravero R, Ardissino G, Colageo U, Staffa P, Bruschetta E, Maroni S, Karvela E, Spagarino E, Ruggeri V, Jura R.
G Ital Nefrol. 2016 Jul-Aug;33(4). pii: gin/33.4.14. Italian.
PMID: 27545639

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.
J Nephrol. 2016 Mar 19. [Epub ahead of print]
PMID: 26995002

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.
Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026.
PMID: 26880462
Free Article

Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome.
Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E.
Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-2153.
PMID: 26644486

Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.
Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, Paracchini V, Tel F, Possenti I, Belingheri M, Civitillo CF, Sardini S, Ceruti R, Baldioli C, Tommasi P, Parola L, Russo F, Tedeschi S.
Eur J Pediatr. 2016 Apr;175(4):465-73. doi: 10.1007/s00431-015-2642-1.
PMID: 26498648

A rapid and sensitive method to measure the functional activity of Shiga toxins in human serum.
Arfilli V, Carnicelli D, Ardissino G, Torresani E, Scavia G, Brigotti M.
Toxins (Basel). 2015 Nov 4;7(11):4564-76. doi: 10.3390/toxins7114564.
PMID: 26556372
Free PMC Article

Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.
Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V.
Am J Kidney Dis. 2015 Jul;66(1):172-3. doi: 10.1053/j.ajkd.2015.04.010. No abstract available.
PMID: 26111906

Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Grenda R, Jarmużek W, Rubik J, Prokurat S, Miklaszewska M, Drozdz D, Zachwieja K, Ardissino G, Hofer J.
Pediatr Transplant. 2015 Sep;19(6):E130-4. doi: 10.1111/petr.12537.
PMID: 26087050

In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'.
Ardissino G, Possenti I, Tel F.
Am J Kidney Dis. 2015 Feb;65(2):342-3. doi: 10.1053/j.ajkd.2014.05.028. No abstract available.
PMID: 25616633

Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome.
Ardissino G, Daccò V, Testa S, Civitillo CF, Tel F, Possenti I, Belingheri M, Castorina P, Bolsa-Ghiringhelli N, Tedeschi S, Paglialonga F, Salardi S, Consonni D, Zoia E, Salice P, Chidini G.
Pediatr Nephrol. 2015 Feb;30(2):345-52. doi: 10.1007/s00467-014-2918-0.
PMID: 25149851

Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.
Pediatrics. 2014 Jun;133(6):e1769-71. doi: 10.1542/peds.2013-2921.
PMID: 24843058
Free Article

Co-infection in children with bloody diarrhea caused by Shiga toxin-producing Escherichia coli: data of the North Italian HUS Network.
Ardissino G, Possenti I, Salardi S, Tel F, Colombo E, Testa S, Daprai L, Picicco D, Colombo RM, Torresani E.
J Pediatr Gastroenterol Nutr. 2014 Aug;59(2):218-20. doi: 10.1097/MPG.0000000000000420.
PMID: 24824362

Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases.
Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M.
Am J Kidney Dis. 2014 Oct;64(4):633-7. doi: 10.1053/j.ajkd.2014.01.434.
PMID:24656451

Time to change the definition of hemolytic uremic syndrome.
Ardissino G, Possenti I, Tel F, Testa S, Paglialonga F.
Eur J Intern Med. 2014 Feb;25(2):e29. doi: 10.1016/j.ejim.2013.12.002. No abstract available.
PMID: 24360866

Skin involvement in atypical hemolytic uremic syndrome.
Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A.
Am J Kidney Dis. 2014 Apr;63(4):652-5. doi: 10.1053/j.ajkd.2013.09.020.
PMID:24290245

Eculizumab for atypical hemolytic uremic syndrome in pregnancy.
Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M.
Obstet Gynecol. 2013 Aug;122(2 Pt 2):487-9. doi: 10.1097/AOG.0b013e31828e2612.
PMID:23884270

Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.
Bu F, Borsa N, Gianluigi A, Smith RJ.
Clin Dev Immunol. 2012;2012:370426. doi: 10.1155/2012/370426. Review.
PMID:23251215
Free PMC Article

The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.
Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJ, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L.
J Matern Fetal Neonatal Med. 2012 Nov;25(11):2322-5. doi: 10.3109/14767058.2012.694923.
PMID:22594569

Bioimpedance analysis and cardiovascular status in pediatric patients on chronic hemodialysis.
Paglialonga F, Ardissino G, Galli MA, Scarfia RV, Testa S, Edefonti A.
Hemodial Int. 2012 Oct;16 Suppl 1:S20-5. doi: 10.1111/j.1542-4758.2012.00743.x.
PMID:23036032

Stampa

Cinque per mille
Cinque per mille
Cinque per mille
Cinque per mille
Bomboniere solidali
Cinque per mille
Momenti Solidali
Questo sito utilizza cookie tecnici per migliorare la tua navigazione e cookie di analisi statistica di terze parti. Se vuoi saperne di più o negare il consenso a tutti o ad alcuni cookie Clicca qui 
Se accedi a un qualunque elemento sovrastante questo banner acconsenti all'uso dei cookie.